Avalo Therapeutics's 15min chart shows KDJ Death Cross, bearish Marubozu pattern.

Avalo Therapeutics' 15-minute chart has triggered a KDJ Death Cross, accompanied by a Bearish Marubozu on August 26, 2022, at 11:45. This indicates a shift in the stock price's momentum towards the downside, with a potential for further decline. Sellers are currently in control of the market, and the bearish momentum is likely to persist.

Title: Avalo Therapeutics: Bearish Signals in 15-Minute Chart

Avalo Therapeutics' 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu on August 26, 2022, at 11:45. This combination of technical indicators signals a shift in the stock's momentum towards the downside, potentially leading to further decreases in the stock price. The dominance of sellers in the market suggests that bearish momentum is likely to continue.

The KDJ Death Cross occurs when the K line of the KDJ indicator crosses below the D line, indicating a potential shift in the stock's momentum towards the downside. The Bearish Marubozu candlestick pattern, characterized by a long body with no shadows above or below, suggests that the stock is being driven by strong selling pressure. This combination of indicators follows a broader trend of narrowing Bollinger Bands and KDJ Golden Cross formations observed in several other stocks, including ASGN and Cushing NextGen [1].

Technical analysis provides valuable insights into potential stock price movements, but it is crucial for investors to consider these signals in conjunction with fundamental analysis and broader market conditions. As of July 7, 2025, several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts. Positive Outlook: Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [1]. Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [1]. CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [1]. Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1]. Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [1]. Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [1]. Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [1]. Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [1]. JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [1]. Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [1]. Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [1]. MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [1]. Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [1]. Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [1]. Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [1]. Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [1]. Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [1]. Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [1]. Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [1]. Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [1]. PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [1]. Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [1].

Investors and financial professionals should closely monitor Avalo Therapeutics' progress and the results of its clinical trials. The company's pipeline includes other promising assets such as quisovalimab, an anti-LIGHT mAb, and AVTX-008, a BTLA agonist fusion protein. AVTX-009 is differentiated by its high affinity and neutralizing activity against IL-1β, a central driver in the inflammatory process [2].

References:
[1] https://www.ainvest.com/news/chart-industries-triggers-kdj-golden-cross-bullish-momentum-builds-marubozu-candle-2508-55/
[2] https://www.ainvest.com/news/avalo-therapeutics-speculative-buy-avtx-009-lotus-results-2508-23/